Emco Ltd – Steady Current

Emco posted a net sales growth of 36% YoY to Rs 3.4bn for Q4FY08 and 44% to Rs 9.4bn for the full fiscal. Project division revenues have picked up pace during H2FY08, contributing 30% of net sales for the fiscal. Management expects an even higher revenue share from this division in FY09, at 45%. EBITDA margins were up by 155bps during Q4FY08 to 14.2% and by 50bps for FY08 to 13.7%. Net profit saw a growth of 98% YoY for the quarter and 59% for the year.

Emco’s order book stands at Rs 11bn, which is 1.2x FY08 sales. The healthy order backlog and bright outlook for the project division indicate good revenue flows over the next two years.

Emco is trading at 10x one-year forward P/E, which is a 61% discount to peer company, ABB.

2 Years of market media service – Nifty Watch Freebie

This site in its new form came to life 2 years ago on June 7th. Since tomorrow is a holiday for markets we thought of announcing it today.

As a birthday bash, we would like to give away an Excel Spreadsheet to track Live NSE Indices S&P CNX NIFTY, S&P CNX DEFTY, S&P CNX 500 , NIFTY MIDCAP 50, CNX NIFTY JUNIOR CNX MIDCAP, CNX IT, CNX 100, BANK NIFTY.

You can also get live stock quotes of companies in Nifty, IT, Banking, Midcap 50 and Junior Nifty.This is useful to employees of companies where they block NSE / Kotak websites.

Usage:
Enable Macros and Enable Auto Refresh and you are all set to keep track of the market.

For Readers who are Stock Researchers based on Technical Analysis, we are willing to provide access to NSE Cash Market Data from 1995 and NSE Derivates Market Data from 2001.

Transport Corporation of India

Transport Corporation of IndiaTCI’s Net sales rose by 12.7% YoY to Rs3.3bn. However, sales are not comparable YoY due to the hive off of fuel pump stations. Excluding the revenues generated from the fuel pumps, sales rose by 17.8%
YoY.

EBITDA grew by 9.9% YoY to Rs 229 mn. EBITDA margins were stable YoY but improved substantially by 188bps QoQ to 7.0% due to improved performance from the TCI Seaways division. depreciation. Interest cost grew by 38.5% YoY to Rs 43 mn due to higher borrowings. Depreciation fell by 104.5% YoY to (Rs 2.5 mn) due to a change in the depreciation policy.

TCI’s supply chain division has added new customers like ITC foods division, Ceat Tyres, P&G, Spinach, etc. TCI also added ~8.0 lac sq ft of warehouse space during FY08. XPS, the Courier division of TCI recorded a 20% growth.

IT spend strong amidst declining profits in US

Indian IT EmployeesDespite the ongoing sluggishness in American corporate profits (BFSI segment), overall US IT spending remained robust in 1Q08. Most Indian IT services companies have acknowledged delays/slowdown in ramps especially for Financial Services customers in 1H08, but expect a recovery in 2H08.

Indian IT players continued their market share gains in the global arena with 35% YoY revenue growth in Q1-2008. Offshoring is likely to be the mega-trend for IT Services and expect Indian IT players to continue to gain market share.

Technology spending as a percentage of profits peaked in Q1-2000 and has constantly declined since then and is currently holding at 25-30% levels.

Inflation to Rise Post Hikes

Yesterday we reported about the hike in petroleum products and excise duties. Post-hike, the Wholesale Price Index is expected to rise by 55 bps only on account of the hike in these 3 products.

The hikes also meant increase in consumer’s burden by Rs211 bn (US$4.9 bn or 0.39% of GDP) and the government will bear tax losses amounting to Rs226.6 bn (US$5.3bn or 0.42% of GDP) in F2009 (12 months ended March 2009).

The combined central plus state deficit including the off-budget expenditure items is expected to be about 8.9% of GDP in F2009 (from 9.3% earlier).

Lupin Laboratories in Top 5 Pharma Companies

Lehman Brothers has initiated coverage on Lupin Laboratories as the company enters the big 5 league in Indian pharmaceuticals. Lupin has successfully scaled up operations in India and the US and has now attained critical size and hopes to be a $1bn company in Fy2008-09.

Lupin has reduced its dependence on anti-tuberculosis and cephalosporin products over the years. It has enhanced its presence in the chronic segment instead, with (more…)